Ordering Recommendation

Assesses genetic risk of abnormal drug metabolism for CYP2C19 substrates. May aid in drug selection and dose planning for drugs metabolized by CYP2C19.


Polymerase Chain Reaction (PCR)/Fluorescence Monitoring




5-10 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation

Lavender (EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature


Unacceptable Conditions

Plasma or serum. Specimens collected in sodium heparin or lithium heparin. Frozen specimens in glass collection tubes.


Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month

Reference Interval

By report

Interpretive Data

Background Information for CYP2C19:
The cytochrome P450 (CYP) isozyme 2C19 is involved in the metabolism of many drugs. Variants in the gene that code for CYP2C19 will influence pharmacokinetics of CYP2C19 substrates, and may predict or explain non-standard dose requirements, therapeutic failure or adverse reactions.
Autosomal codominant.
CYP2C19 gene variants affect enzyme function.
Variants Tested:
See the Additional Technical Information document.
Clinical Sensitivity:
: Polymerase chain reaction (PCR) and fluorescence monitoring.
Analytical Sensitivity and Specificity
: Greater than 99 percent.
: Only the targeted CYP2C19 variants will be detected by this panel, and assumptions about phase and content are made to assign alleles. Publicly available sources such as the www.pharmvar.org or www.pharmgkb.org provide guidance on phenotype predictions and allele frequencies. Diagnostic errors can occur due to rare sequence variations. Risk of therapeutic failure or adverse reactions with CYP2C19 substrates may be affected by genetic and non-genetic factors that are not detected by this test. This result does not replace the need for therapeutic drug or clinical monitoring. 

Please note the information contained in this report does not contain medication recommendations, and should not be interpreted as recommending any specific medications. Any dosage adjustments or other changes to medications should be evaluated in consultation with a medical provider.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Compliance Category

Laboratory Developed Test (LDT)


Whole blood is the preferred specimen. Saliva samples that yield inadequate DNA quality and/or quantity will be reported as inconclusive if test performance does not meet laboratory-determined criteria for reporting.

Hotline History


CPT Codes



Component Test Code* Component Chart Name LOINC
2008936 CYP2C19 Phenotype 79714-2
3001509 2C19GENO Specimen 31208-2
3001510 CYP2C19 Genotype 57132-3
3001511 2C19GENO Interpretation 50398-7
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • 2C19
  • amitriptyline
  • antidepressants
  • clomipramine
  • clopidogrel
  • CYP2C19
  • Cytochrome P450 2C19 Genotype
  • dexlansoprazole
  • doxepine
  • escitalopram
  • imipramine
  • lansoprazole
  • omeprazole
  • pantoprazole
  • Plavix
  • PPIs
  • protein pump inhibitors
  • rabeprazole
  • sertraline
  • SSRI
  • TCA
  • trimipramine
  • voriconazole